Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2020 09:25 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participantsTopline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with...